Zanubrutinib monotherapy in CD79B‐mutated relapsed or refractory diffuse large B‐cell lymphoma: A multicenter Phase 2 study

[Current treatment strategies for diffuse large B-cell lymphoma].

Recent advances in treatment strategies for DLBCL are summarized, several novel agents are under active clinical development, and future perspectives are discussed.

Cell Lymphomas: Recent Phase III - CD20×CD3 Bispecific Antibodies in Relapsed/Refractory B Evidence Durability, and Safety

Clinicopathological Features of DLL3 Expression and T‐Cell Infiltration in LCNEC: Insights From Pathology and Clinical Response to Tarlatamab

Evaluated DLL3 expression and CD8+ tumor‐infiltrating lymphocytes (TILs) infiltration in LCNEC and investigated their clinical significance and association with tarlatamab efficacy.

Outcome after first relapse post‐immunochemotherapy in older adults with Philadelphia‐negative B‐cell acute lymphoblastic leukemia: A GRAALL study

Inotuzumab (InO)‐based frontline regimens have significantly improved the survival of older patients with Philadelphia‐negative (Ph–) B‐cell acute lymphoblastic leukemia (B‐ALL). Yet, outcome after relapse is not reported for this population.

Dinutuximab beta with TEMIRI chemotherapy in relapsed/refractory neuroblastoma: Real-world insights into the open question of GD2 expression

Bone/bone marrow metastasis seems to be more sensible to this treatment compared to soft tissue lesions and the percentage of GD2-positive tumor cells tends to decrease under chemoimmunotherapy pressure.

Outcomes of ibrutinib plus lenalidomide combination in patients with large Bcell lymphoma refractory to or relapsing after CAR-T-cell therapy and who failed or were ineligible for bispecific antibodies: a multicenter real-world REALI-T study.

Not available.